Stem Cell Therapy for Colon Cancer – The Ritz Herald

An article published in Experimental Biology and Medicine(Volume 245, Issue 6, March 2020)examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model.

Mesenchymal stem (MSCs), a category of adult stem cells, are being evaluated as a therapy for numerous cancers.MSCs are excellent carriers for tumor treatment because they migrate to tumor tissues, can be genetically modified to secrete anticancer molecules and do not elicit immune responses.Clinical trials have shown that MSCs carrying modified genes can be used to treat colon cancer as well as ulcerative colitis. However, some studies have demonstrated MSCs can differentiate into cancer-associated fibroblasts and promote tumor growth.Therefore, additional studies are needed to evaluate the safety of MSCs for targeted treatment of colon cancer.

In the current study, Dr. Liu and colleagues examined the effects of mesenchymal stem cells (MSCs) from three sources (bone marrow, adipose, and placenta) on colon cancer cells.MSCs from all three sources promoted tumor growth and metastasis in vivo. In vitro studies demonstrated that MSCs promote colon cancer cell stemness and epithelial to mesenchymal transition, which would enhance tumor growth and metastasis respectively.Finally, the detrimental effects of MSCs could be reversed by blocking IL-8 signaling pathways. Dr. Ma, a co-author of the study, said that Mesenchymal stem cells have a dual role: promoting and/or suppressing cancer. Which effect is dominant depends on the type of tumor cell, the tissue source of the MSC and the interaction between the MSC and the cancer cell. This is the major issue in the clinical application research of MSCs, and additional preclinical experimental data will be needed to evaluate the safety of MSCs for colon cancer treatment.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said: Lui and colleagues have performed elegant studies on the impact of mesenchymal stem cells (MSCs), from various sources, upon the proliferation, stemness, and metastasis of colon cancer stem cells (CSCs) in vitro and in vivo. They further demonstrate that IL-8 stimulates the interaction between colon CSCs and MSCs, and activates the MAPK signaling pathway in colon CSCs.This provides a basis for the further study of MSCs as a biologic therapy for colon cancer.

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit sebm.org.

See the original post here:

Stem Cell Therapy for Colon Cancer - The Ritz Herald

Read more
Column: Scientific advancements in the time of COVID-19 and what they offer us – The Daily Tar Heel

The coronavirus, otherwise known as COVID-19, has dramatically transformed the lives of people around the globe. It has decimated economies, overwhelmed health care systems and affected families in unimaginable ways. However, in spite of the havoc that it has caused, COVID-19 has furthered our understanding of pandemic control beyond anything that we've known before. Most importantly, it has proven the resilience of the scientific and healthcare communities.

Data sharing is a huge aspect of how epidemiologists can begin to understand diseases. It provides insight in terms of the populations that the conditions affect, as well as the speed and extent of transmission. This is something that health care professionals at UNC and the Icahn School of Medicine at Mount Sinai are attempting to address with the establishment of SECURE-IBD.

SECURE-IBD is a project that is focused on collecting disease-specific COVID-19 data, with an emphasis on patients with inflammatory bowel disease, such as Crohns disease and colitis, who contract the virus.

The registry takes patients with varying disease symptoms and hospitalizations and connects them with specialists and healthcare professionals. The tool has inspired other disease-specific registries, and can be used to identify things like potential drugs and treatments. It also connects doctors and scientists in a way that hasnt been this widely done in the past.

Data sharing has also allowed researchers to collaborate on projects in order to study coronavirus at an expedited pace. The virus was sequenced within a week of discovery and has been made publicly available. Courses at UNC, such as Computer Science 555 (Bioalgorithms), have even integrated the genome into everyday classwork. And although academic life has generally been branded with the 'publish or perish' mindset for decades, publishing is the last thing on anyones minds at the moment.

View post:

Column: Scientific advancements in the time of COVID-19 and what they offer us - The Daily Tar Heel

Read more
What does the public know about COVID-19? – University of Miami

Survey aims to shed light on any misconceptions so that public agencies can address them.

Two University of Miami researchers are investigating how much people truly know about COVID-19and whether they would be willing to take a drug to prevent themselves from getting the disease, if one existed.

Dr. Dushyantha T. Jayaweera, a professor of medicine in the infectious disease research unit at the Miller School of Medicine, and public health graduate student Russell Saltzman often work together on clinical trials. Recently, they were brainstorming ways to help slow the spread of coronavirus, and Saltzman thought it would be helpful to find out if people are receiving the correct information about the virus that has prompted a global pandemic.

Ive heard people say that there has been a lot of inconsistent messaging by the authorities about COVID-19, so we wanted to figure out where the misconceptions lie, said Saltzman, who is also a clinical research coordinator at the Interdisciplinary Stem Cell Institute at the Miller School.

Both Saltzman and Jayaweera acknowledged the constant government advisories are a lot to keep up witheven for health care professionalsbut said it is their goal to ensure that the public has as much information as possible to stay healthy.

Things are moving so fast that its easy to be out of the loop, so its important to know what people know to inform the policymakers, Saltzman said. If we can identify gaps in knowledge, that can help focus efforts for disseminating information about the disease.

After about a month of data collection, the two will publish their research, making it accessible to government agencies and state health departments, Jayaweera said.

To gather the information, Saltzman created a 10-minute electronic survey and made it available through social media and several email listservs. The researchers hope participants will share it with friends so they can gain 10,000 participants from around the country.

Also through the survey, Jayaweera and Saltzman hope to gauge public attitudes toward a study that would examine the use of a drug called hydroxychloroquine (HCQ) as amedication topreventor slow the transmission of COVID-19. In two to three weeks, Jayaweera will begin a clinical trial funded by the National Institutes of Health examining whether the drug can help prevent infection in health care providers and shorten the disease course in general.

To participate in the survey, visit https://umiami.qualtrics.com/jfe/form/SV_blNe3xhV8Xx4uGN.

See more here:

What does the public know about COVID-19? - University of Miami

Read more
Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus – PR Web

Dr. Bart Rademaker Stem Cell Therapy Info, Coronavirus

TAMPA, Fla. (PRWEB) April 02, 2020

Dr. Bart Rademaker, the long-time plastic surgeon who has branched out into stem cell therapy, is offering online classes to patients and doctors who are interested in learning more about regenerative medicine and the potential benefits on health in particular during this time with the coronavirus or COVID-19. Rademaker, has offered the therapy in his office for years and has been contacted by physicians and patients who wish to find out more information on the benefits it could have for those combating the virus as clinical trials are proceeding in many parts of the world.. The classes will be available beginning in April 2020 and include podcasts, blogs and other forms of information that are available online.

The coronavirus has turned the world upside down and people are trying to gather any information they can. Ive heard medical experts tell people to drink warm tea or water every 20 minutes. Ive heard patients say they read that you can kill the virus with stem cell therapy. There is too much information going out there right now and I want to help patients and medical professionals get the facts on it. Based on my experience and my communication with experts in the field of regenerative medicine, I feel that I can offer some assistance. Dr. Bart Rademaker

One of the main things the doctor wishes to stress to people who are unsure how to minimize exposure is that they need to follow the guidelines put in place by their government and information provided on personal hygiene and safety. This includes washing hands thoroughly with water and soap rather than rely on hand soap. Trying to avoid contact with your eyes and mouth unless youve recently washed your hands. Taking vitamins to strengthen your immune system. Staying away from people and avoiding areas like grocery stores as long as possible are other good recommendations provided that people should follow.

People are not sure what to do because the information comes at them so quickly. Even doctors are not sure when their patient asks them if stem cell therapy is a safe option to prevent or treat the coronavirus. When I have doctors calling me just because they saw that I offer regenerative medicine information online, I knew it was time to start getting aggressive with these classes and offer my assistance to everyone.

For more information you can call our team at: 727-748-7389

About Dr. Bart Rademaker

Dr. Bart Rademaker is based in Tampa, Florida and has over 20 years of experience as a well-respected medical professional. He has affiliations with several hospitals including Morton Plant and Mease Countryside. His degree is from Erasmus University Rotterdam Faculty of Medicine and added regenerative medicine to his practice four years ago.

Share article on social media or email:

See original here:

Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus - PR Web

Read more
Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of…

CAMBRIDGE, England--(BUSINESS WIRE)-- Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administrations (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. The papers, in Nature Scientific Reports1 and Toxicology and Applied Pharmacology2, focus on application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.

The CiPA Initiative (www.cipaproject.org), which began in July 2013 following a workshop at the US FDA, has the objective to revise and enhance the regulatory framework assessing cardiac safety of new chemical entities. Under current guidelines, new therapeutics undergo initial assessment of proarrhythmic risk by measuring activity against the hERG cardiac ion channel, before progressing to studies in preclinical animal models and ultimately, a Thorough QT interval study in the clinic. The CiPA initiative aims to extend the use of advances in early electrophysiology-based cardiac ion channel screening, in silico predictive modelling, and human induced pluripotent stem cell derived cardiomyocytes to improve the accuracy and reduce the cost of predicting the cardiac liability of new drug candidates. Metrions research forms part of the first stage of the proposed harmonisation work, to provide clarity on how to standardise cardiac ion channel assays to ensure they deliver consistent data for in silico models of clinical cardiac arrythmia risk.

The first paper1, published in Nature Scientific Reports on 27th March 2020 by an international group of authors drawn from 20 different commercial and academic laboratories, including Metrion Biosciences, was coordinated by the Health and Environmental Sciences Institute (HESI). It reviews data from a multi-year, multi-site collaboration across industry, academia and the FDA regulatory agency to optimize experimental protocols and reduce experimental variability and bias. The goal of the study was to guide the development of best practices for the use of automated patch clamp technologies in early cardiac safety screening. High quality in vitro cardiac ion channel data is required for accurate and reliable characterisation of the risk of delayed repolarisation and proarrhythmia in the human heart and to guide subsequent clinical studies and regulatory submissions.

The second paper2, to be published formally in Toxicology and Applied Pharmacology paper on 1st May 2020 but currently available online, uses automated patch clamp data from the CiPA consortium to address the lack of statistical quantification of variability, which hinders the use of primary hERG potency data to predict cardiac arrhythmia. The consortium establishes a more systematic approach to estimate hERG block potency and safety margins.

Dr Marc Rogers, CSO, Metrion Biosciences, said: The Metrion team has been a participant in the international CiPA Initiative since inception and we are now pleased to be able to announce the publication of our data from this global collaborative scientific effort. We believe these projects will make a significant contribution to the eventual revision of cardiac safety testing guidelines by the FDA and other international regulatory agencies. They also contribute to deepening our knowledge of the underlying causes of proarrhythmia, which will help prevent early attrition of potentially promising drugs.

Contributing organisations to the Nature Scientific Reports CiPA study include: Charles River Laboratories; Bayer AG; Sophion Bioscience A/S; Nanion Technologies; GlaxoSmithKline PLC; Pfizer; Sanofi R&D; Astra Zeneca; BSYS GmbH; Bristol-Myers Squibb Company; Eurofins Discovery; Merck; Metrion Biosciences Ltd.; Natural and Medical Science Institute at the University of Tbingen; Northwestern Feinberg School of Medicine, Chicago; Roche Innovation Center Basel; Novoheart; Health and Environmental Sciences Institute, Washington, DC; AbbVie.

Contributing organisations to the Toxicology and Applied Pharmacology hERG study include: Center for Drug Evaluation and Research, Food and Drug Administration; Eli Lilly and Company; AstraZeneca; CiPA LAB; NMI-TT GmbH; Sophion Bioscience A/S; B'SYS GmbH; The Ion Channel Company; F. Hoffmann-La Roche AG; Eurofins Discovery; Bristol-Myers Squibb; Merck & Co., Inc; Metrion Biosciences Ltd.; Nanion Technologies; Charles River Laboratories; Bayer AG; University of Nottingham; Universit de Lille.

For more information on Metrions fully integrated Cardiac Safety Screening / CiPA Screening service, please visit: https://www.metrionbiosciences.com/services/cardiac-safety-screening/

Merion Biosciences comprehensive cardiac safety testing White Paper The changing landscape of cardiac safety will also be available on the Companys website from 13th April 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005408/en/

Read more here:

Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of...

Read more
Symtomax: the science behind producing high quality medical cannabis – Health Europa

Indeed, such research has enabled consumers to look beyond the assumption that all forms of cannabis will make them high an assumption attributed to tetrahydrocannabinol (THC), the psychoactive compound within the cannabis plant. Now, non-psychoactive compounds such as Cannabidiol (CBD) are starting to enter consumer markets in a variety of products such as vapes, edibles, and dietary supplements.

However, the cannabis plant (Cannabis Sativa), has not solely been used for recreational purposes. For thousands of years, cannabis has been used in ancient medicine for its pain-relieving qualities. At the present time, medical research has suggested that cannabinoids can be used by a large number of patients worldwide to lessen the symptoms of conditions as wide-ranging as anxiety and Parkinsons disease, to migraines and multiple sclerosis.

With the prevalence of medicinal cannabis on the up, the cannabis industry is changing, which begs the question how is it produced, and what should we as an industry be doing to ensure that the manufacture of medicinal cannabis is always of the highest possible quality?

Many would point towards cultivation as an important factor in the production of high-quality medicinal cannabis.

In order for medical cannabis to thrive, certain environmental conditions are required for optimal growth; these include overall air quality, genetics, adequate light, temperature, humidity, soil and water quality.

There is a reason that California in particular is hailed as a hub for the medical cannabis industry; its greatest asset is its warm climate, rich soil and abundant sunlight all which make the outdoor production of high-quality cannabis a viable prospect. This of course is a very similar climate to Portugal, where Symtomax have started the development of their medical cannabis cultivation facility, an enormous 105-hectare site in the Alentejo region of the country.

Of course, similar conditions can be replicated using greenhouses, where ventilation then becomes the most crucial factor. The right ventilation prevents the growth of mildew, or mould, and overheating, so an intake and outtake fan on the ceiling or the top of the grow room are required for adequate ventilation.

Likewise, temperature is also a crucial factor. The ideal temperature for a medical cannabis plant to grow tends to be between 20 and -30 degrees Celsius; such conditions mean they are able to grow stronger and thicker stems, with denser buds. At temperatures below 15 degrees Celsius, plant growth begins to slow, so it is crucial that this is monitored closely.

Indeed, more and more companies are understanding the benefits in investing in state-of-the-art greenhouses, to create the best conditions for cannabis growth. For example, Symtomax has recently begun work on new greenhouses with advanced engineering work to ensure all cannabis plants receive optimal growing conditions.

However, producing the highest quality medicinal cannabis doesnt stop at the growing stage. Indeed, given the vast array of potential health benefits, experts are always in the process of conducting new studies into the cannabis plant itself, so that manufacturers and health professionals alike can better understand its properties. In particular, research into lesser known cannabinoids and the qualities they possess are key drivers in the improvement of medicinal cannabis quality.

CBD (cannabidiol) is one of the most common compounds (also known as a cannabinoid), and has been found to possess anti-inflammatory, calming and pain-relieving properties due to its interactions with the serotonin receptors on the brain. As it stands, there is insufficient evidence for CBD to be formally recognised as medicine; that said new studies are emerging every day and consequently, more consumers are experimenting with various CBD products, including oil or edible supplements to relieve ailments.

However, there is more to the cannabis plant than CBD. In recent years, the focus of research is shifting towards other compounds, such as CBG (cannabigerol) and TCHV (tetrahydrocannabivarin). CBG in particular has shown promise as an antibacterial agent and its anti-inflammatory properties. Known widely as the stem cell of cannabis, but despite its vast medical appeal and health benefits, the compound is notoriously expensive to produce.

Consequently, CBG is not readily available for the consumer market, meaning that the majority are largely unaware of its potential benefits. That said, with more research being conducted into this cannabinoid, the tides could change over the coming years.

Increasingly, formulation technologies, which act as a bridge between the active components (such as CBD or THC) and the finished products (like CBD oil), are playing an important role in the development of cannabinoid products. Proper formulation strategies lead to products with increased efficacy, better dose control, decreased variability, and increased patient acceptance.

So, knowing the best extraction processes for the right cannabinoids is vital in ensuring the high quality of a product. Likewise, a solid grounding in how different combinations of compounds will most benefit consumers is fundamental to new innovations and discoveries within the industry.

Already, expertise surrounding different formulation technologies have resulted in some exciting innovations. For example, the Symtomax CBD oral tab, which is built on a thin film and adheres to the inside of the cheek. The proprietary technology releases cannabinoids in a controlled, timed manner through the lining of the mouth. Oral Tab can be developed to release doses at different times, so that this method is a practical option for both those needing an instant dose, and those requiring a slower release, over a longer timeframe. The flexibility of time release is therefore improved, as is the quantity of CBD available to enter the blood stream, therefore contributing to better efficiency and systemic absorption rate than any other delivery methods available at present.

All in all, although medicinal cannabis is still a young industry in the western world, and naturally, there is still much research to be done in order to dispel pre-existing taboos and prove its efficacy, there is a lot to be said for its increasing popularity. I look forward to seeing how the industry, and indeed the products, advance over the coming years.

Paul Segal is the Chairman & co-founder of Symtomax. Symtomax have been approved by Infarmed to start the development of Europes largest medical cannabis facility. The organisation is dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.

Recommended Related Articles

View post:

Symtomax: the science behind producing high quality medical cannabis - Health Europa

Read more
Leukapheresis Market Is Booming Worldwide | Asahi Kasei Medical Co. Ltd, Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc. -…

The Leukapheresis market research report is required to show a gigantic development inside the upcoming years. The investigators likewise have dissected downsides with on-going Organic Semiconductor patterns and in this manner the open doors that are giving to the expanded development of the business. The report gives the viewpoint of this aggressive scene of worldwide markets. The report passes points of interest that started from the examination of the focused on market

leukapheresis market is expected to rise from its initial estimated value of USD 19.9 million in 2018 to an estimated value of USD 36.1 million by 2026 registering a CAGR of 7.7% in the forecast period of 2019-2026. Leukapheresis is a procedure used for separating white blood cells from a sample of blood. It can be performed to reduce the count of very high white blood cell, to attain cells for various research purposes and to obtain autologous blood cells for further transplant back into patient. It is a type of apheresis, used for separating out a particular constituent of blood and to return the remaining part back to the circulation.

Leukapheresis Market 2027 Top Players (Market Analysis, Opportunities, Demand, Forecasting)

Click HERE To get SAMPLE COPY OF THIS REPORT (Including Full TOC, Table & Figures) [emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-leukapheresis-market

The titled segments and sub-section of the market are illuminated below:

By Type (Leukapheresis Devices, Leukapheresis Disposables),

Application (Research Applications, Therapeutic Applications),

End User (Blood Component Providers and Blood Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Transfusion Centers),

Geographical Insights:

In-depth qualitative analyses include identification and investigation of the following aspects:

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify global extended reality market in every aspect of the classification from perspectives of Technology, Component, Device Type, Industry Vertical, End-user, and Region.

Competitive Analysis: Leukapheresis Market

The global leukapheresis market is highly fragmented and the major players have used different strategies such as mergers, partnerships, expansions, innovative product launches, agreements, joint ventures, acquisitions and others to increase their footprints in this market. The report includes market shares of leukapheresis market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Leukapheresis Market competitive landscapes provides details by topmost Key Players like

Asahi Kasei Medical Co. Ltd, Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc., Macopharma, Fresenius SE & Co. KGaA, HemaCare, Caltag Medsystem Ltd, AllCells, StemExpress, PPA, Key Biologics LLC, ZenBio Inc., Precision for Medicine Inc., BioIVT, Digital Pharmacist Inc., Lmb Technologie GmbH, Grifols, S.A, Bioelettronica and Kaneka Pharma Europe NV.

Browse in-depth TOC on Global Leukapheresis Market60- Tables220- Figures350 Pages

The Study Objectives of the Global Leukapheresis Market Research Report are:

Table of Content:

Chapter One: Global Leukapheresis Industry Market Research Report

Chapter Two: Industry Chain Analysis

Chapter Three: Global Leukapheresis Market, by Type

Chapter Four: Leukapheresis Market, by Application

Chapter Five: Global Leukapheresis Production, Value ($) by Region (2015-2020)

Chapter Six: Global Leukapheresis Production, Consumption, Export, Import by Regions (2015-2020)

Chapter Seven: Global Leukapheresis Market Status and SWOT Analysis by Regions

Chapter Eight: Competitive Landscape

Chapter Nine: Global Leukapheresis Market Analysis and Forecast by Type and Application

Chapter Ten: Leukapheresis Market Analysis and Forecast by Region

Chapter Eleven: New Project Feasibility Analysis

Chapter Twelve: Research Finding and Conclusion

Chapter Thirteen: Appendix

Read More: https://www.databridgemarketresearch.com/toc/?dbmr=global-leukapheresis-market

For each of the aforementioned regions and countries, detailed analysis and data for annual revenue (demand and production) are available for 2020-2027. The breakdown of all regional markets by country and the key national markets by Technology, Component, and Industry Vertical over the forecast years are also included.

How will this Market Intelligence Report Benefit You?

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read the rest here:

Leukapheresis Market Is Booming Worldwide | Asahi Kasei Medical Co. Ltd, Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc. -...

Read more
Experimental drug APN01 prevents COVID-19 infection in the lab – News-Medical.Net

With the world gripped with the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a frantic rush to find an effective drug that can be used to treat the disease.

Researchers from the University of British Columbia, in collaboration with others, have found an experimental drug that can inhibit the SARS-CoV-2 virus from infecting host cells. Their study titled, "Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2," was published in the latest issue of the journal Cell.

In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. Credit: IMBA/Tibor Kulcsar

What were the highlights of the study?

As of today, 6th April 2020, the virus has affected 1,341,907 individuals worldwide and killed 74,476. Many of these deaths were caused by severe lung injury.

Dr. Josef Penninger, study leader, and his team are working on ways to inhibit SARS-CoV-2's capacity to infect human host cells. They write that in their previous study, they had explained the mechanism of infection caused by this virus and how angiotensin-converting enzyme 2 (ACE2) receptor plays a vital role in the infection. The enzyme ACE2 has the capacity to protect the lungs from injury caused by the virus. This also provided an explanation regarding the severe lung damage, respiratory failure, kidney and blood vessels, and eventual death seen in some of the individuals.

The team wrote that the ACE2 receptor and the SARS-CoV-2 interaction could be one of the critical areas for drug targets since this is vital for the virus to infect the human host cells. They speculate that human recombinant soluble ACE2 (hrsACE2) could be vital to block the invasion of the host cell by the SARS CoV-2.

Penninger, a professor at UBC's faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC, said, "We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic." He added, "This work stems from an amazing collaboration among academic researchers and companies, including Dr. Ryan Conder's gastrointestinal group at STEMCELL Technologies in Vancouver, Nuria Montserrat in Spain, Drs. Haibo Zhang and Art Slutsky from Toronto and especially Ali Mirazimi's infectious biology team in Sweden, who have been working tirelessly day and night for weeks to better understand the pathology of this disease and to provide breakthrough therapeutic options."

What was done?

Penninger and his team from the University of Toronto and the Institute of Molecular Biology in Vienna tried to find the link between cardiovascular disease, lung damage, and the protein. They explained that at present, there are no antiviral drugs that can definitively kill the virus, and this new approach could be the only option.

Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michael's Hospital and professor at the University of Toronto, who was part of this study explained, "Our new study provides very much needed direct evidence that a drug -- called APN01 (human recombinant soluble angiotensin-converting enzyme 2 - hrsACE2) -- soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19."

APN01 is a recombinant human Angiotensin Converting Enzyme 2 (rhACE2) under Phase-2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). Recently, ACE2 has been shown to be the cellular entry receptor for the novel coronavirus SARS-CoV-2. Therefore APEIRON initiated now a clinical Phase II study in Austria, Germany, and Denmark for treatment of COVID-19 and is planning a clinical study in China in patients infected with SARS-CoV-2. APEIRON Biologics AG.

For this study, the team used biomedically engineered organoids in the lab that mimicked human blood vessels and kidneys. These are essentially clumps of cells that act as the whole organ within the human body and are grown from human stem cells. On these organoids, the team then used hrsACE2 and found that it could prevent the entry of the coronavirus into the host cells. The decrease in the viral load affecting the host cells was by a factor of 1,000-5,000, they wrote.

Nria Montserrat, ICREA professor at the Institute for Bioengineering of Catalonia in Spain, part of the team, added, "Using organoids allows us to test in a very agile way treatments that are already being used for other diseases, or that are close to being validated. In these moments in which time is short, human organoids save the time that we would spend to test a new drug in the human setting."

For this study, they used a Swedish patient who tested positive for COVID-19 in early February 2020. The SARS-CoV-2 virus was isolated from the nasopharyngeal samples of the patient. They grew the virus in the Vero E6 cells and looked at its genetic sequence using Next-Generation Sequencing (Genbank accession number MT093571).

What was found?

The researchers wrote, "Here we show that clinical-grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000." They added that using an equivalent of mouse rsACE2 on the cells had no such inhibitory effect of the virus on the human organoids. They add, "We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2."

They wrote, "hrsACE-2 can inhibit SARS-CoV-2 infection in a dose-dependent manner hrsACE2 has already undergone clinical phase 1 and phase 2 testing and is being considered for the treatment of COVID-19."

For this study, they found the efficacy of clinical-grade hrsACE2. They infected the Vero-E6 cells with different viral loads of SARS-CoV-2. They named them "103 plaque-forming units (PFUs; MOI 0.02), 105 PFUs (MOI 2), and 106 PFUs (MOI 20)," respectively. Infection of cells after an hour of administration of hrsACE2 followed by washing and incubation without hrsACE2 showed that at 15 hours post-infection, there was a significant SARS-CoV-2 infection in the cells. They tested the viral RNA in the cells using qRT-PCR.

Conclusions and implications

Penninger added, "The virus causing COVID-19 is a close sibling to the first SARS virus. Our previous work has helped to rapidly identify ACE2 as the entry gate for SARS-CoV-2, which explains a lot about the disease. Now we know that a soluble form of ACE2 that catches the virus could be indeed a very rational therapy that specifically targets the gate the virus must take to infect us. There is hope for this horrible pandemic."

The team concludes that as such, it cannot be predicted that the effects of the hrsACE2 would remain the same during the whole course of the illness. What can be seen is the prevention of the virus from infecting host cells, they wrote. They also warn that this study did not test the effect of the trial drug on lung organoids, and as lungs are one of the main organs that are damaged, the study needs further exploration. Also, human trials are needed to see the effect of the drug on actual patients of COVID-19. They sign off, "To address these issues, further studies are needed to illuminate the effect of hrsACE2 at later stages of infection in vitro and in vivo."

The study was funded by the Canadian federal government.

Sources:

Journal reference:

See more here:

Experimental drug APN01 prevents COVID-19 infection in the lab - News-Medical.Net

Read more
Synthetic Stem Cells Market Size 2020: Opportunities and Forecasts 2026 – Science In Me

The Report Titled on Synthetic Stem Cells Market which provides COVID19 Impact analysis on Market Size (Production, Capacity, Value, Values & Consumption), Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis, Impact of Domestic and Market Players. Synthetic Stem Cells Market detailed study of historical and present/future market data. Economic growth, GDP (Gross Domestic Product), and inflation are some of the elements included in this report to offer crystal clear picture of the Synthetic Stem Cells industry at global level.

Synthetic Stem Cells Market competitive landscapes provides details by topmost manufactures like (North Carolina State University, Zhengzhou University), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Synthetic Stem Cells[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2395700

Synthetic Stem Cells Market Report Offers Comprehensive Assessment of:

1) Executive Summary, 2) Synthetic Stem Cells Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Synthetic Stem Cells Market Background, 7) Synthetic Stem Cells industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Synthetic Stem Cells Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles etc.

Scope of Synthetic Stem Cells Market:Synthetic stem cells offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies. Additionally, these cells have better preservation stability and the technology is generalizable to other types of stem cells.

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Cardiovascular Diseases Neurological Disorders Other Diseases

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Cancers Wounds and Injuries Musculoskeletal Disorders Blood disorders

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2395700

Synthetic Stem Cells Market: Regional analysis includes:

The Synthetic Stem Cells Market Report Can Answer The Following Questions:

Who are the key manufacturers of Synthetic Stem Cells market? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Synthetic Stem Cells?

Economic impact on Synthetic Stem Cells industry and development trend of Synthetic Stem Cells industry.

What will the Synthetic Stem Cells market size and the growth rate be in 2026?

What are the Synthetic Stem Cells market challenges to market growth?

What are the upstream raw materials and manufacturing equipment of Synthetic Stem Cells? What is the manufacturing process of Synthetic Stem Cells?

What are the key factors driving the Synthetic Stem Cells market?

What are the Synthetic Stem Cells market opportunities and threats faced by the vendors in the Synthetic Stem Cells market?

Contact:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the rest here:

Synthetic Stem Cells Market Size 2020: Opportunities and Forecasts 2026 - Science In Me

Read more
Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production – ENGINEERING.com

Parker Hannifin has sponsored this post.

Cell therapies promise treatments for serious illnesses, but require automation and manufacturing expertise to scale up production for research and products. (Image courtesy of Parker Hannifin.)

Cellular therapies and bio-fabrication are two of the most revolutionary treatments for serious illnesses to be developed in the early 21st century, offering the hope of cures where once only symptomatic treatments were available. The 2006 discovery of Induced Pluripotent Stem Cells (iPSCs) formed a catalyst for research and development into these new therapeutic approaches. Stem cell therapies offer promising avenues for the treatment of devastating illnesses such as diabetes, cancer, heart disease and even neurological diseases.

Tailored cell therapies using iPSCs are considered to be the new Third Pillar of the drug and treatment industry, standing alongside small molecules and biologics as tools for treatment. However, the widespread research and treatment using cell therapies requires mass-produced iPSCs to be available in quantitywhich means advanced manufacturing techniques.

Cells are tiny living, complex organisms; they must be handled with precision and accuracy. Automated handling equipment needs a heightened level of dexterity and control. (Image courtesy of Parker Hannifin.)

Scaling up the production of iPSCs requires investmentsome of which is already in place with two deals: $70 million to the New Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to advance U.S. leadership in the biopharmaceutical industry, and an 87-member coalition funded by the Defense Department called ARMI-BioFab USA, which aims to develop the next-generation techniques needed to repair and replace cells, tissues and organs for wounded military service veterans.

The key to success in the scale-up of production is advanced automation, which will improve the manufacturing process used to fabricate cell colonies.

Currently, most research and cell fabrication involves a significant amount of manual work and decision-making, which can be error-prone and represents a bottleneck in attempts to scale these fabrication processes.

One way to improve the manufacturing processes related to cell therapies is by partnering with experienced automation and manufacturing industry leaders, who can share their expertise. An example of this is the partnership between Parker Hannifin and CellX Technologies. Together, these companies have developed a platform to help researchers and clinicians quantify key morphological stem cells, automate the handling process and perform cell maintenance.

Current cell therapy research is hampered by difficulties with a lack of large field-of-view and high-resolution optics when imaging live cell cultures. This makes it difficult to monitor and quantify changes to the cells. Available devices and equipment for sampling, transfer or deletion of specific cells or colonies also lack the rigorous accuracy that manufacturing-scale production would require. Instead, visual assessment and manual transfer by lab technicians is the usual methodsacrificing speed and production volume.

An automated, image-based system would enable accurate quantitative metrics of biological performance and will be applicable at a cell-by-cell or a colony-by-colony basis, among other benefits.

Automated cell-handling equipment needs to be precise and finely calibrated in order to handle delicate cells with the necessary dexterity and control. Three primary handling techniques are used for this very difficult automation task:

Combining capabilities for these three functions into a single platform will enable multiple benefits, including improved reproducibility and quality of cells for research and products, reduce variability and costs from manual processes, improved lot traceability and documentation, and define quantitative process quality attributes and metrics.

Parker Hannifins expertise in manufacturability, digital pathology and additive manufacturing lends itself directly to the development of the CellX platform. CellX enables automation of the scanning and identification processes, and pairs this with cell selection and precision placement.

The CellX Device, developed by Parker Hannifin and CellX Technologies, combines large field-of-view imaging with precision instrumentation, fluidics, and documentation and control capabilities. (Image courtesy of Parker Hannifin.)

CellX also needed customization of standard products. Parker Hannifin has decades of experience in close tolerance special purpose fluidics and actuator technology, and developed enabling technology for the CellX central core, which consists of a high-quality automated inverted microscope and CCD camera with brightfield and fluorescent imaging capabilities.

Some of the specialized equipment that Parker Hannifin helped develop for CellX includes a load and removal station for disposable cell-picking tips, and environmentally controlled workspace to maintain sterility and oxygen levels, and an integrated sensor to accurately locate each new tip.

The combined precision and imaging capabilities of the CellX platform enable rapid data collection and high repeatability, which means researchers can rely on accurate data, healthy cell colonies and quantitative, reproducible standards for cell therapy development. Parker Hannifin has a proven history of developing new tools and instruments for manufacturing processes with their partner OEMsand in the case of CellX, accelerating the development of the future of cell therapies.

To learn more about Parker Hannifins development of the CellX platform, including use cases and details on the full complement of customized equipment and enabling features, download the full whitepaper from Parker Hannifin.

See original here:

Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production - ENGINEERING.com

Read more